KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to $1.3 billion.

  • Biomarin Pharmaceutical's Cash & Equivalents rose 8507.83% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 8507.83%. This contributed to the annual value of $942.8 million for FY2024, which is 2485.87% up from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported Cash & Equivalents of $1.3 billion as of Q3 2025, which was up 8507.83% from $1.2 billion recorded in Q2 2025.
  • Biomarin Pharmaceutical's 5-year Cash & Equivalents high stood at $1.3 billion for Q3 2025, and its period low was $580.1 million during Q1 2023.
  • In the last 5 years, Biomarin Pharmaceutical's Cash & Equivalents had a median value of $724.5 million in 2022 and averaged $783.7 million.
  • As far as peak fluctuations go, Biomarin Pharmaceutical's Cash & Equivalents tumbled by 3923.81% in 2021, and later soared by 8507.83% in 2025.
  • Over the past 5 years, Biomarin Pharmaceutical's Cash & Equivalents (Quarter) stood at $587.3 million in 2021, then grew by 23.37% to $724.5 million in 2022, then grew by 4.22% to $755.1 million in 2023, then grew by 24.86% to $942.8 million in 2024, then skyrocketed by 32.59% to $1.3 billion in 2025.
  • Its Cash & Equivalents stands at $1.3 billion for Q3 2025, versus $1.2 billion for Q2 2025 and $1.0 billion for Q1 2025.